Front Desk: 469-391-0070
Teprotumumab: Effective Thyroid Eye Disease Treatment
Summary of Key Points
Teprotumumab is a prescription medication specifically developed to treat thyroid eye disease (TED), a condition often linked to Graves’ disease. This medication works by reducing inflammation and protecting the tissues around the eyes from damage. It is administered through intravenous (IV) infusion over a period of several months. Teprotumumab can help relieve symptoms such as eye bulging (exophthalmos) and double vision (diplopia). It is important to consult a healthcare provider before starting or making any changes to your treatment plan.
Names of the Medication
US Brand Name: Tepezza
Generic Name: Teprotumumab
The generic name refers to the active ingredient’s chemical composition, while the brand name is the marketed version of the medication. Both names are often listed together for clarity.
Pharmacologic Category
Teprotumumab belongs to the class of medications known as Monoclonal Antibodies. Other drugs in this category include:
- Rituximab (Rituxan)
- Adalimumab (Humira)
- Infliximab (Remicade)
Dosing Guidelines
Teprotumumab is approved for the treatment of thyroid eye disease and related conditions. Below are the dosing recommendations for adults:
Thyroid Eye Disease (TED)
Initial Dose: 10 mg/kg administered via IV infusion.
Subsequent Doses: 20 mg/kg administered every three weeks, for a total of eight infusions.
Length of Treatment: Approximately five months.
Conditions Related to Thyroid Eye Disease
Teprotumumab is primarily approved for thyroid eye disease (TED), which is often associated with conditions such as Graves’ disease, autoimmune thyroiditis, hyperthyroidism, hypothyroidism, ocular inflammation, diplopia, exophthalmos, orbital inflammation, and vision impairment. The dosing schedule for these related conditions is the same as that for TED.
Always consult your doctor before making any changes to your dosage or starting a new treatment. If you need guidance, our telemedicine services can connect you with a healthcare provider quickly and conveniently.
Dosage Forms and Strengths
Form: Intravenous (IV) infusion
Strength: 500 mg per vial
Administration Instructions
Teprotumumab is administered as an intravenous (IV) infusion, which delivers the medication directly into the bloodstream through a vein. The first infusion typically takes about 90 minutes, while subsequent infusions are usually completed in approximately 60 minutes. This treatment is provided in a healthcare setting, such as a clinic or hospital, under the supervision of a trained medical professional. Attending all scheduled infusions is essential to achieve the best possible outcomes from your treatment.
Contraindications
Contraindications refer to specific conditions or circumstances in which a medication should not be used due to potential risks. Understanding these contraindications is crucial before beginning any treatment. The following are the contraindications for Teprotumumab:
- Pregnancy: Teprotumumab can harm an unborn baby. It is contraindicated during pregnancy because it may interfere with fetal development, potentially leading to serious birth defects.
- Breastfeeding: The use of Teprotumumab is not recommended while breastfeeding, as it is unclear whether the drug passes into breast milk and could pose risks to a nursing infant.
- Uncontrolled Diabetes: Teprotumumab may worsen blood sugar levels. Patients with poorly managed diabetes are at an increased risk of complications such as hyperglycemia (high blood sugar).
- Inflammatory Bowel Disease (IBD): Patients with IBD, including Crohn’s disease or ulcerative colitis, may experience worsening symptoms while using Teprotumumab. This is because the medication can affect the immune system, potentially triggering inflammation in the gastrointestinal tract.
Drug-to-Drug Interactions
Teprotumumab, a medication used to treat thyroid eye disease, can interact with other drugs, potentially reducing its effectiveness or increasing the likelihood of side effects. It is crucial to inform your healthcare provider about all medications you are currently taking, including over-the-counter drugs, vitamins, and supplements. Below are some known interactions associated with Teprotumumab:
Insulin or other diabetes medications: (e.g., Humalog [insulin lispro], Glucophage [metformin]) – Teprotumumab may raise blood sugar levels, which can complicate diabetes management. Close monitoring of blood glucose levels is recommended if you are taking these medications alongside Teprotumumab.
Immunosuppressants: (e.g., Humira [adalimumab], Enbrel [etanercept]) – Combining Teprotumumab with immunosuppressive drugs may increase the risk of infections or other immune-related complications. Your healthcare provider may adjust your treatment plan to minimize these risks.
Live vaccines: (e.g., MMR [measles, mumps, rubella vaccine], FluMist [live influenza vaccine]) – Teprotumumab can suppress immune system activity, potentially reducing the effectiveness of live vaccines or increasing the risk of contracting the infection the vaccine is designed to prevent. Discuss vaccination timing with your doctor before starting treatment.
Teprotumumab in Pregnancy
Is it safe to take Teprotumumab during pregnancy?
No, Teprotumumab is not considered safe for use during pregnancy. This medication can harm a developing fetus and may lead to birth defects. Women who are pregnant or planning to become pregnant should avoid using Teprotumumab. If you are of childbearing age, it is essential to use reliable contraception while undergoing treatment and for at least six months after your final dose. If you become pregnant while taking Teprotumumab, contact your healthcare provider immediately to discuss next steps.
Teprotumumab While Breastfeeding
Is it safe to take Teprotumumab while breastfeeding?
Teprotumumab is not recommended for use while breastfeeding. There is currently insufficient data to determine whether this medication passes into breast milk or if it could harm a nursing infant. If you are breastfeeding or planning to breastfeed, consult your healthcare provider to explore alternative treatment options that may be safer for you and your baby.
Estimated Cost of Teprotumumab
The cost of Teprotumumab can be significant, especially without insurance coverage. A 30-day supply typically ranges from $14,000 to $15,000 per vial when using a GoodRx coupon. Since Teprotumumab is administered via infusion, the total cost of treatment may vary depending on the number of infusions required and the facility where the treatment is provided. To better understand your financial responsibility, contact your insurance provider to confirm whether this medication is covered under your plan.
Possible Alternatives to Teprotumumab
If Teprotumumab is not an appropriate option for you, there are alternative treatments and lifestyle adjustments that may help manage thyroid eye disease and related conditions. Always consult your healthcare provider before making any changes to your treatment plan. You may also consider scheduling a telemedicine appointment with one of our providers to discuss these alternatives in detail.
Thyroid Eye Disease (TED): Alternatives include corticosteroids (e.g., prednisone) to reduce inflammation, radiation therapy, or surgical procedures to address eye misalignment or bulging. Lifestyle modifications, such as quitting smoking and wearing sunglasses to reduce light sensitivity, can also provide relief.
Graves’ Disease: Treatment options include antithyroid medications (e.g., methimazole), radioactive iodine therapy, or thyroidectomy (surgical removal of the thyroid gland). Managing stress and maintaining a balanced diet may also help alleviate symptoms.
Autoimmune Thyroiditis: This condition is typically managed with hormone replacement therapy (e.g., levothyroxine) to regulate thyroid function. Regular monitoring of thyroid hormone levels is essential to ensure effective treatment.
Hyperthyroidism: Common treatments include antithyroid medications, radioactive iodine therapy, or surgery. Lifestyle changes, such as reducing caffeine intake and managing stress, can help control symptoms.
Hypothyroidism: The primary treatment is hormone replacement therapy (e.g., levothyroxine). A nutrient-rich diet that includes iodine and selenium may support thyroid health.
Ocular Inflammation: Anti-inflammatory medications, such as corticosteroids or nonsteroidal anti-inflammatory drugs (NSAIDs), may be prescribed. Cold compresses and lubricating eye drops can provide additional symptom relief.
Diplopia (Double Vision): Treatment options include prism glasses or surgical correction. Eye exercises recommended by an eye specialist may also help improve double vision over time.
Exophthalmos (Bulging Eyes): In severe cases, surgery may be necessary to reposition the eyes. Corticosteroids or radiation therapy may also be used to reduce swelling and inflammation.
Orbital Inflammation: Treatment may involve corticosteroids, immunosuppressive medications, or surgery to relieve pressure in the eye socket. Cold compresses can provide temporary relief from discomfort.
Vision Impairment: Depending on the underlying cause, treatments may include corrective lenses, surgery, or medications. Regular eye exams are essential to monitor and address any changes in vision promptly.
Recent Updates on Teprotumumab Research
Teprotumumab, a groundbreaking treatment for thyroid eye disease, continues to be a focal point of ongoing research. As a relatively new medication, studies are delving into its long-term effects and exploring potential applications beyond its current use. Recent findings underscore its effectiveness in alleviating symptoms, particularly for individuals with moderate to severe thyroid eye disease. Researchers are also investigating whether Teprotumumab could offer benefits for other autoimmune conditions that affect the eyes or thyroid. However, additional research is necessary to confirm these possibilities.
Key Findings on Teprotumumab for Thyroid Eye Disease
A landmark 2022 study published in the journal Ophthalmology revealed that Teprotumumab significantly reduces eye bulging (exophthalmos) and double vision (diplopia) in patients with thyroid eye disease. These results highlight its potential as a highly effective treatment option for this condition. Furthermore, ongoing clinical trials are assessing the long-term safety and efficacy of Teprotumumab. The findings from these studies are expected to provide valuable insights into its sustained benefits and broader impact on patient outcomes.
Future Directions in Teprotumumab Research
Researchers are actively exploring the potential for Teprotumumab to address a wider range of conditions beyond thyroid eye disease. This includes its possible role in managing other autoimmune disorders and its function as an IGF-1R inhibitor for various eye-related diseases. These investigations aim to deepen our understanding of how Teprotumumab works and to identify new ways it could benefit a broader spectrum of patients.
Learn More About Teprotumumab Treatment Options
If you are considering Teprotumumab as a treatment option or want to stay updated on the latest research, scheduling a telemedicine consultation with one of our experienced providers can be a helpful first step. They can assess whether this innovative therapy is suitable for your specific needs. Additionally, they can provide detailed information about the infusion process, potential side effects, and cost considerations, ensuring you have all the information necessary to make an informed decision.
